On September 23, 2024, Invivyd, Inc., a biopharmaceutical company, released detailed virology data and analysis of SARS-CoV-2 structural biology, predicting anticipated neutralization activity for its investigational monoclonal antibody, PEMGARDA™ (pemivibart). The press release, filed as Exhibit 99.1 with the SEC, highlighted the in vitro pseudovirus neutralization potency of PEMGARDA against SARS-CoV-2 variants KP.3.1.1 and LB.1, which aligns with previous variants tested. Invivyd's ongoing SARS-CoV-2 spike analyses have shown consistent structural stability of the pemivibart binding site, which has historically predicted sustained in vitro neutralization activity. The company also noted that potential emerging variants, such as XEC and LP.1, have mutations distal from the pemivibart binding site, suggesting they would not significantly alter pemivibart activity. Routine neutralization analysis will continue...Show More

On September 23, 2024, Invivyd, Inc., a biopharmaceutical company, released detailed virology data and analysis of SARS-CoV-2 structural biology, predicting anticipated neutralization activity for its investigational monoclonal antibody, PEMGARDA™ (pemivibart). The press release, filed as Exhibit 99.1 with the SEC, highlighted the in vitro pseudovirus neutralization potency of PEMGARDA against SARS-CoV-2 variants KP.3.1.1 and LB.1, which aligns with previous variants tested. Invivyd's ongoing SARS-CoV-2 spike analyses have shown consistent structural stability of the pemivibart binding site, which has historically predicted sustained in vitro neutralization activity. The company also noted that potential emerging variants, such as XEC and LP.1, have mutations distal from the pemivibart binding site, suggesting they would not significantly alter pemivibart activity. Routine neutralization analysis will continue to assess potential changes. Invivyd contracts with LabCorp’s Monogram Biosciences lab for independent virology assessments to monitor the changing potency of pemivibart as the virus evolves. The company's proprietary INVYMAB™ platform combines viral surveillance and predictive modeling with advanced antibody engineering to rapidly generate new monoclonal antibodies to address evolving viral threats. Invivyd received emergency use authorization (EUA) from the U.S. FDA for PEMGARDA in March 2024 for pre-exposure prophylaxis of COVID-19 in certain immunocompromised individuals.